Qingbo Xu | Clinical Biotechnology | Best Researcher Award

Published on by Biotechnology Scientist

Prof. Dr. Qingbo Xu | Clinical Biotechnology | Best Researcher Award

Professor of Cardiology at Zhejiang University Medical School | China

Prof. Dr. Qingbo Xu is a leading authority in cardiovascular medicine, widely recognized for his pioneering contributions to vascular biology, stem cell research, and cardiovascular regeneration. His career spans decades of academic leadership, clinical collaboration, and translational science, positioning him as an internationally respected figure in medical research. Prof. Dr. Qingbo Xu has played a key role in uncovering the mechanisms of vascular disease and in developing innovative therapeutic strategies aimed at improving patient outcomes. His dedication to advancing scientific discovery while mentoring the next generation of researchers has firmly established him as a cornerstone in the global cardiovascular research community.

Profile

Orcid

Education

Prof. Dr. Qingbo Xu began his academic journey in medicine with a strong grounding in both clinical and biomedical sciences, equipping him to address the complexity of cardiovascular health and disease. His studies combined medical training with advanced research in molecular biology and pathology, which provided the expertise to investigate cardiovascular mechanisms at both cellular and systemic levels. International research experiences and postdoctoral fellowships further broadened his scientific perspective, allowing him to integrate diverse methodologies into a multidisciplinary framework. This educational foundation has been central to shaping his unique approach to vascular biology and regenerative medicine.

Experience

Prof. Dr. Qingbo Xu has held prestigious positions at leading universities and medical institutions across the world. His academic journey includes professorships and research leadership roles where he directed pioneering programs in vascular biology, cardiovascular sciences, and regenerative therapies. His career also encompasses advisory positions on international scientific boards, editorial responsibilities in high-impact journals, and membership in distinguished medical societies. Prof. Dr. Qingbo Xu has contributed extensively to international collaborations, leading multicenter projects and organizing influential scientific meetings. Through his leadership, he has built bridges between basic research and clinical application, driving innovation in cardiovascular medicine on a global scale.

Research Interest

Prof. Dr. Qingbo Xu’s research interests center on vascular biology, progenitor cell biology, and cardiovascular regeneration. He has been at the forefront of studies on endothelial and smooth muscle progenitor cells, focusing on their role in vascular repair, remodeling, and disease progression. His investigations extend into the mechanisms of atherosclerosis, restenosis, and vascular inflammation, highlighting how molecular signaling and epigenetic regulation govern these processes. A major theme of his work is regenerative medicine, particularly the use of stem cell-based therapies and tissue engineering to repair vascular injury and restore cardiovascular function. Prof. Dr. Qingbo Xu’s integrative research approach continues to provide insights that guide both fundamental science and translational medicine.

Award

Prof. Dr. Qingbo Xu has been honored with numerous awards for his outstanding achievements in cardiovascular research. These distinctions reflect his influence as a scientist, mentor, and leader. Prestigious fellowships, scientific prizes, and international recognitions celebrate his pioneering contributions to vascular biology and regenerative medicine. He has also been acknowledged for his contributions to medical education and for fostering scientific exchange between nations. These honors underscore not only his scientific impact but also his role as a global ambassador for cardiovascular research, advancing the field and inspiring future generations of scientists.

Publication Top Notes

Title: PIEZO1-activated donor lymphatic remodeling integrates with autologous lymphangiogenesis to enhance vein graft patency in mice
Year: 2025

Title: Altered lipid metabolism promoting cardiac fibrosis is mediated by CD34+ cell-derived FABP4+ fibroblasts
Year: 2024

Title: Single-Cell Mapping of Large and Small Arteries During Hypertensive Aging
Year: 2024

Title: ATP promotes resident CD34+ cell migration mainly through P2Y2-Stim1-ERK/p38 pathway
Year: 2023

Title: The Impact of Stem/Progenitor Cells on Lymphangiogenesis in Vascular Disease
Year: 2022

Conclusion

Prof. Dr. Qingbo Xu stands as a visionary in cardiovascular research whose legacy is defined by innovation, leadership, and scientific excellence. His contributions have redefined the understanding of vascular biology, progenitor cells, and regenerative medicine, bringing laboratory discoveries closer to clinical application. Through his publications, mentorship, and international collaborations, he has advanced not only science but also the careers of countless young researchers. Prof. Dr. Qingbo Xu’s work remains a driving force in the pursuit of therapies that address some of the most challenging cardiovascular diseases, ensuring that his influence will continue to shape the future of medicine for years to come.

WEI CAO | Clinical Biotechnology | Young Researcher Award

Published on by Biotechnology Scientist

Prof. WEI CAO | Clinical Biotechnology | Young Researcher Award

Professor | Shanghai Jiao Tong University School of Medicine Affiliated Ninth People’s Hospital | China

Wei Cao, MD, PhD, is a distinguished Professor at the Department of Oral and Maxillofacial–Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine. Renowned for his expertise in head and neck cancers, especially oral squamous cell carcinoma, he has contributed significantly to understanding tumor biology, recurrence mechanisms, and therapeutic resistance. With an H-index of and citations, he has authored impactful research shaping the field of oral oncology. His editorial appointments in high-impact journals and active membership in global medical associations further reflect his academic stature and leadership in oncology research.

Profile

Scopus | Orcid

Education

Wei Cao earned his Diploma in Oral Medicine from Zhengzhou University School of Medicine. He then pursued his MD and PhD at Shanghai Jiao Tong University School of Medicine, completing his doctoral training in Head and Neck Surgical Oncology in. To enhance his research scope and gain international exposure, he undertook postgraduate training in the Department of Oncology and Diagnostic Sciences at the University of Maryland Dental School in the USA. His educational journey has provided him with a strong foundation in both clinical practice and biomedical research.

Experience

Over his career, Wei Cao has progressed through academic and clinical ranks, starting as a Fellow in the Department of Oral and Maxillofacial–Head and Neck Oncology and later serving as a Surgeon  in the same department. He was appointed Associate Professor in and Consultant before becoming Professor. Alongside his hospital responsibilities, he plays key editorial roles in journals such as Frontiers in Oncology and Technology in Cancer Research & Treatment, and serves on multiple editorial boards including BMC Cancer and Cancer Biology & Medicine. His professional affiliations include the American Association for Cancer Research and the Royal Society of Medicine.

Research Interest

Cao’s research focuses on the molecular mechanisms underlying the initiation, progression, and recurrence of oral and head and neck cancers. He investigates tumor microenvironment interactions, immunotherapy responses, and the role of non-coding RNAs in cancer biology. His work also explores novel biomarkers for prognosis, mechanisms of therapy resistance, and the development of personalized treatment strategies. Integrating single-cell transcriptomics, molecular pathology, and clinical data, his research aims to improve survival outcomes and quality of life for cancer patients.

Award

Wei Cao’s research excellence has been recognized with numerous honors, including the CYTO Student Travel Award, Excellent Doctoral Dissertation in Shanghai, and multiple national and institutional science and technology awards such as the 2nd Prize from the Chinese Medical Association and the National Ministry of Education.he was named among the “Outstanding Young Oncologists” by the Chinese Society of Clinical Oncology and received the Outstanding Young Scholar and Kowloon Outstanding Young Talent Awards from Shanghai Jiao Tong University School of Medicine.

Publication Top Notes

Cao has an extensive publication record in high-impact journals. Seven representative works include:

Title:  Single-cell transcriptomics reveals cell atlas and identifies cycling tumor cells responsible for recurrence in ameloblastoma,” Int J Oral Sci.
Year: 2024
Citations: 2

Title:  LINC02454-CCT complex interaction is essential for telomerase activity and cell proliferation in head and neck squamous cell carcinoma, Cancer Lett.
Year: 2024
Citations: 3

Title:  CXC ligand 13 orchestrates an immunoactive microenvironment and enhances immunotherapy response in head and neck squamous cell carcinoma,” Int J Immunopathol Pharmacol.
Year: 2024
Citations: 1

Title:  Yin Yang 1-Induced Long Noncoding RNA DUXAP9 Drives the Progression of Oral Squamous Cell Carcinoma by Blocking CDK1-Mediated EZH2 Degradation, Adv Sci (Weinh).
Year: 2023
Citations: 6

Title:  EVI2B Is a Prognostic Biomarker and Is Correlated with Monocyte and Macrophage Infiltration in Osteosarcoma,” Biomolecules.
Year: 2023
Citations: 5

Title:  Cancer cells co-opt nociceptive nerves to thrive in nutrient-poor environments, Cell Metab.
Year: 2022
Citations: 44

Title: Targeting cellular metabolism in head and neck cancer precision medicine era: A promising strategy to overcome therapy resistance, Oral Dis.
Year: 2023
Citations: 8

Conclusion

Professor Wei Cao has established himself as a leader in oral and head and neck oncology through a career that bridges clinical excellence and groundbreaking research. His contributions to elucidating molecular mechanisms, identifying prognostic biomarkers, and advancing therapeutic strategies have significantly impacted patient care and cancer biology. With a robust portfolio of high-impact publications, prestigious awards, and leadership roles in international journals, he continues to shape the future of cancer research. His work reflects a commitment to innovation, interdisciplinary collaboration, and improving clinical outcomes for patients facing complex oncological challenges.